Initial proof of concept can open the market to treat other serious inflammatory diseases and so target the $106B inflammatory market with a more safe and effective peptide inhibitor.
The global market for anti-inflammatory treatments is expected to reach $106.1 billion by 2020.
Inflammation is triggered by the defense system of the body as a normal response to external influences and is the natural mechanism which attempts to eliminate any injury, clear dead cells and heal injured tissues. Sometimes, the bodies defense system triggers inflammation against its own cells, resulting in diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD).
At this point in time, there is a real requirement for better and safer novel anti-inflammatory treatments that have no side effects. Existing treatments such as steroids, ibuprofen, paracetamol etc., all have serious drawbacks and limitations from this perspective.
Initial target = mild-moderate disease (85%) and replace current treatments.
If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.
If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.